Abnormalities in micturition: Difference between revisions

Jump to navigation Jump to search
Line 116: Line 116:
| style="background: #DCDCDC; text-align: center;" |[[Urethritis]]
| style="background: #DCDCDC; text-align: center;" |[[Urethritis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |–
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |–
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 135: Line 135:
| style="background: #DCDCDC; text-align: center;" |[[Pyelonephritis]]
| style="background: #DCDCDC; text-align: center;" |[[Pyelonephritis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |–
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |–
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |–
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 154: Line 154:
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginitis]]
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 173: Line 173:
| style="background: #DCDCDC; text-align: center;" |[[Cervicitis]]
| style="background: #DCDCDC; text-align: center;" |[[Cervicitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 191: Line 191:
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Prostatitis]]  
| style="background: #DCDCDC; text-align: center;" |[[Prostatitis]]  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 210: Line 210:
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Epididymoorchitis]]
| style="background: #DCDCDC; text-align: center;" |[[Epididymoorchitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 231: Line 231:
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Anatomic]]
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Anatomic]]
| style="background: #DCDCDC; text-align: center;" |[[Urethral stricture]]
| style="background: #DCDCDC; text-align: center;" |[[Urethral stricture]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 250: Line 250:
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Benign prostatic hyperplasia|Benign prostatic hyperplasia (BPH)]]
| style="background: #DCDCDC; text-align: center;" |[[Benign prostatic hyperplasia|Benign prostatic hyperplasia (BPH)]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 270: Line 270:
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Drug]]
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Drug]]
| style="background: #DCDCDC; text-align: center;" |[[Spermicide|Spermicides]]
| style="background: #DCDCDC; text-align: center;" |[[Spermicide|Spermicides]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 289: Line 289:
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Cyclophosphamide]]
| style="background: #DCDCDC; text-align: center;" |[[Cyclophosphamide]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 309: Line 309:
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Endocrine disorders]]
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Endocrine disorders]]
| style="background: #DCDCDC; text-align: center;" |[[Atrophic vaginitis]]
| style="background: #DCDCDC; text-align: center;" |[[Atrophic vaginitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 328: Line 328:
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Endometriosis]]
| style="background: #DCDCDC; text-align: center;" |[[Endometriosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 345: Line 345:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* [[Dysmenorrhea]]
* [[Dyspareunia]]
* [[Dyschezia]]
|-
|-
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Malignancy]]
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Malignancy]]
| style="background: #DCDCDC; text-align: center;" |[[Bladder cancer]]
| style="background: #DCDCDC; text-align: center;" |[[Bladder cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 367: Line 370:
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginal disorders|Vulvovaginal cancer]]
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginal disorders|Vulvovaginal cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 388: Line 391:
| style="background: #DCDCDC; text-align: center;" |[[Genitourinary system|Genitourinary instrumentation]]
| style="background: #DCDCDC; text-align: center;" |[[Genitourinary system|Genitourinary instrumentation]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 406: Line 409:
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Pelvic]] [[irradiation]]
| style="background: #DCDCDC; text-align: center;" |[[Pelvic]] [[irradiation]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 426: Line 429:
| style="background: #DCDCDC; text-align: center;" |[[Trauma]]
| style="background: #DCDCDC; text-align: center;" |[[Trauma]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |

Revision as of 20:53, 28 June 2018

Micturation Abnormalities Microchapters

Overview

Causes

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Classification

Causes

Abnormalities of Micturition Differential Diagnosis

Differentiating the diseases that can cause abnormality in micturition:

Abbreviations: N= Normal, UTI= Urinary tract infection, CBC= Complete blood count, CT= Computed tomography, IBS= Irritable bowel syndrome, DRE= Digital rectal examination,

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging
Fever Urinary symptoms Supra-pubic tenderness Skin lesions Other CBC Electrolytes Urinalysis Ultrasonography CT scan Other
Dysuria Frequency Dribbling Hesitancy Nocturia
Inflammatory Dermatological disorders Lichen sclerosus[1] + + Lichenified plaques N N often shows UTI in women N N N Biopsy
Behcet's syndrome[2][3][4] + + + + N N N N N None
Infectious diseases Cystitis + + + + + + + N Leukopenia N
Urethritis + + + + +
Pyelonephritis + + + ±
Vulvovaginitis + + + + + -
Cervicitis + ± ± - - +
Prostatitis + + + + + +
Epididymoorchitis + + +
Non-inflammatory Anatomic Urethral stricture
Benign prostatic hyperplasia (BPH) + + + + +
Drug Spermicides
Cyclophosphamide +
Endocrine disorders Atrophic vaginitis
Endometriosis +
Malignancy Bladder cancer
Vulvovaginal cancer ±
Iatrogenic Genitourinary instrumentation +
Pelvic irradiation
Trauma ± ±

References

  1. Ventolini G, Patel R, Vasquez R (2015). "Lichen sclerosus: a potpourri of misdiagnosed cases based on atypical clinical presentations". Int J Womens Health. 7: 511–5. doi:10.2147/IJWH.S82879. PMC 4431497. PMID 26056492.
  2. Theodorou C, Floratos D, Hatzinicolaou P, Vaiopoulos G (August 1999). "Neurogenic bladder dysfunction due to Behçet's disease". Int. J. Urol. 6 (8): 423–5. PMID 10466456.
  3. Porru D, Pau AC, Scarpa RM, Zanolla L, Cao A, Usai E (May 1996). "Behçet's disease and the neuropathic bladder: urodynamic features: case report and a literature review". Spinal Cord. 34 (5): 305–7. PMID 8963981.
  4. Cetinel B, Akpinar H, Tüfek I, Uygun N, Solok V, Yazici H (January 1999). "Bladder involvement in Behçet's syndrome". J. Urol. 161 (1): 52–6. PMID 10037367.